Most of the intended management changes after68Ga-DOTATATE PET/CT are implemented

Jeremie Calais, Johannes Czernin, Matthias Eiber, Wolfgang P. Fendler, Jeannine Gartmann, Anthony P. Heaney, Andrew E. Hendifar, Joseph R. Pisegna, J. Randolph Hecht, Edward M. Wolin, Roger Slavik, Pawan Gupta, Andrew Quon, Christiaan Schiepers, Martin S. Allen-Auerbach, Ken Herrmann

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In this prospective referring-physician–based survey, we investigated the definite clinical impact of 68Ga-DOTATATE PET/CT on managing patients with neuroendocrine tumors (NETs). Methods: We prospectively studied 130 patients with 68Ga-DOTATATE PET/ CT referred for initial or subsequent management decisions (NCT02174679). Referring physicians completed one questionnaire before the scan (Q1) to indicate the treatment plan without PET/CT information, one immediately after review of the imaging report to denote intended management changes (Q2), and one 6 mo later (Q3) to verify whether intended changes were in fact implemented. To further validate the Q3 responses, a systematic electronic chart review was conducted. Results: All 3 questionnaires were completed by referring physicians for 96 of 130 patients (74%). 68Ga-DOTATATE PET/CT resulted in intended management changes (Q2) in 48 of 96 patients (50%). These changes were finally implemented (Q3) in 36 of 48 patients (75%). Q3 responses were confirmed in all patients with an available electronic chart (36/96; 38%). Conclusion: This prospective study confirmed a significant impact of 68Ga-DOTATATE PET/CT on the intended management of patients with NETs (50% of changes) and notably demonstrated a high implementation rate (75%) of these intended management changes.

Original languageEnglish (US)
Pages (from-to)1793-1796
Number of pages4
JournalJournal of Nuclear Medicine
Volume58
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Neuroendocrine Tumors
Physicians
Prospective Studies
68Ga-DOTATATE
Surveys and Questionnaires
Therapeutics

Keywords

  • DOTATATE
  • Impact on implemented management
  • Neuroendocrine tumors
  • PET/ CT
  • Somatostatin receptor

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Calais, J., Czernin, J., Eiber, M., Fendler, W. P., Gartmann, J., Heaney, A. P., ... Herrmann, K. (2017). Most of the intended management changes after68Ga-DOTATATE PET/CT are implemented. Journal of Nuclear Medicine, 58(11), 1793-1796. https://doi.org/10.2967/jnumed.117.192450

Most of the intended management changes after68Ga-DOTATATE PET/CT are implemented. / Calais, Jeremie; Czernin, Johannes; Eiber, Matthias; Fendler, Wolfgang P.; Gartmann, Jeannine; Heaney, Anthony P.; Hendifar, Andrew E.; Pisegna, Joseph R.; Randolph Hecht, J.; Wolin, Edward M.; Slavik, Roger; Gupta, Pawan; Quon, Andrew; Schiepers, Christiaan; Allen-Auerbach, Martin S.; Herrmann, Ken.

In: Journal of Nuclear Medicine, Vol. 58, No. 11, 01.11.2017, p. 1793-1796.

Research output: Contribution to journalArticle

Calais, J, Czernin, J, Eiber, M, Fendler, WP, Gartmann, J, Heaney, AP, Hendifar, AE, Pisegna, JR, Randolph Hecht, J, Wolin, EM, Slavik, R, Gupta, P, Quon, A, Schiepers, C, Allen-Auerbach, MS & Herrmann, K 2017, 'Most of the intended management changes after68Ga-DOTATATE PET/CT are implemented', Journal of Nuclear Medicine, vol. 58, no. 11, pp. 1793-1796. https://doi.org/10.2967/jnumed.117.192450
Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP et al. Most of the intended management changes after68Ga-DOTATATE PET/CT are implemented. Journal of Nuclear Medicine. 2017 Nov 1;58(11):1793-1796. https://doi.org/10.2967/jnumed.117.192450
Calais, Jeremie ; Czernin, Johannes ; Eiber, Matthias ; Fendler, Wolfgang P. ; Gartmann, Jeannine ; Heaney, Anthony P. ; Hendifar, Andrew E. ; Pisegna, Joseph R. ; Randolph Hecht, J. ; Wolin, Edward M. ; Slavik, Roger ; Gupta, Pawan ; Quon, Andrew ; Schiepers, Christiaan ; Allen-Auerbach, Martin S. ; Herrmann, Ken. / Most of the intended management changes after68Ga-DOTATATE PET/CT are implemented. In: Journal of Nuclear Medicine. 2017 ; Vol. 58, No. 11. pp. 1793-1796.
@article{3cc7c0064834427397f4300c016e4349,
title = "Most of the intended management changes after68Ga-DOTATATE PET/CT are implemented",
abstract = "In this prospective referring-physician–based survey, we investigated the definite clinical impact of 68Ga-DOTATATE PET/CT on managing patients with neuroendocrine tumors (NETs). Methods: We prospectively studied 130 patients with 68Ga-DOTATATE PET/ CT referred for initial or subsequent management decisions (NCT02174679). Referring physicians completed one questionnaire before the scan (Q1) to indicate the treatment plan without PET/CT information, one immediately after review of the imaging report to denote intended management changes (Q2), and one 6 mo later (Q3) to verify whether intended changes were in fact implemented. To further validate the Q3 responses, a systematic electronic chart review was conducted. Results: All 3 questionnaires were completed by referring physicians for 96 of 130 patients (74{\%}). 68Ga-DOTATATE PET/CT resulted in intended management changes (Q2) in 48 of 96 patients (50{\%}). These changes were finally implemented (Q3) in 36 of 48 patients (75{\%}). Q3 responses were confirmed in all patients with an available electronic chart (36/96; 38{\%}). Conclusion: This prospective study confirmed a significant impact of 68Ga-DOTATATE PET/CT on the intended management of patients with NETs (50{\%} of changes) and notably demonstrated a high implementation rate (75{\%}) of these intended management changes.",
keywords = "DOTATATE, Impact on implemented management, Neuroendocrine tumors, PET/ CT, Somatostatin receptor",
author = "Jeremie Calais and Johannes Czernin and Matthias Eiber and Fendler, {Wolfgang P.} and Jeannine Gartmann and Heaney, {Anthony P.} and Hendifar, {Andrew E.} and Pisegna, {Joseph R.} and {Randolph Hecht}, J. and Wolin, {Edward M.} and Roger Slavik and Pawan Gupta and Andrew Quon and Christiaan Schiepers and Allen-Auerbach, {Martin S.} and Ken Herrmann",
year = "2017",
month = "11",
day = "1",
doi = "10.2967/jnumed.117.192450",
language = "English (US)",
volume = "58",
pages = "1793--1796",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "11",

}

TY - JOUR

T1 - Most of the intended management changes after68Ga-DOTATATE PET/CT are implemented

AU - Calais, Jeremie

AU - Czernin, Johannes

AU - Eiber, Matthias

AU - Fendler, Wolfgang P.

AU - Gartmann, Jeannine

AU - Heaney, Anthony P.

AU - Hendifar, Andrew E.

AU - Pisegna, Joseph R.

AU - Randolph Hecht, J.

AU - Wolin, Edward M.

AU - Slavik, Roger

AU - Gupta, Pawan

AU - Quon, Andrew

AU - Schiepers, Christiaan

AU - Allen-Auerbach, Martin S.

AU - Herrmann, Ken

PY - 2017/11/1

Y1 - 2017/11/1

N2 - In this prospective referring-physician–based survey, we investigated the definite clinical impact of 68Ga-DOTATATE PET/CT on managing patients with neuroendocrine tumors (NETs). Methods: We prospectively studied 130 patients with 68Ga-DOTATATE PET/ CT referred for initial or subsequent management decisions (NCT02174679). Referring physicians completed one questionnaire before the scan (Q1) to indicate the treatment plan without PET/CT information, one immediately after review of the imaging report to denote intended management changes (Q2), and one 6 mo later (Q3) to verify whether intended changes were in fact implemented. To further validate the Q3 responses, a systematic electronic chart review was conducted. Results: All 3 questionnaires were completed by referring physicians for 96 of 130 patients (74%). 68Ga-DOTATATE PET/CT resulted in intended management changes (Q2) in 48 of 96 patients (50%). These changes were finally implemented (Q3) in 36 of 48 patients (75%). Q3 responses were confirmed in all patients with an available electronic chart (36/96; 38%). Conclusion: This prospective study confirmed a significant impact of 68Ga-DOTATATE PET/CT on the intended management of patients with NETs (50% of changes) and notably demonstrated a high implementation rate (75%) of these intended management changes.

AB - In this prospective referring-physician–based survey, we investigated the definite clinical impact of 68Ga-DOTATATE PET/CT on managing patients with neuroendocrine tumors (NETs). Methods: We prospectively studied 130 patients with 68Ga-DOTATATE PET/ CT referred for initial or subsequent management decisions (NCT02174679). Referring physicians completed one questionnaire before the scan (Q1) to indicate the treatment plan without PET/CT information, one immediately after review of the imaging report to denote intended management changes (Q2), and one 6 mo later (Q3) to verify whether intended changes were in fact implemented. To further validate the Q3 responses, a systematic electronic chart review was conducted. Results: All 3 questionnaires were completed by referring physicians for 96 of 130 patients (74%). 68Ga-DOTATATE PET/CT resulted in intended management changes (Q2) in 48 of 96 patients (50%). These changes were finally implemented (Q3) in 36 of 48 patients (75%). Q3 responses were confirmed in all patients with an available electronic chart (36/96; 38%). Conclusion: This prospective study confirmed a significant impact of 68Ga-DOTATATE PET/CT on the intended management of patients with NETs (50% of changes) and notably demonstrated a high implementation rate (75%) of these intended management changes.

KW - DOTATATE

KW - Impact on implemented management

KW - Neuroendocrine tumors

KW - PET/ CT

KW - Somatostatin receptor

UR - http://www.scopus.com/inward/record.url?scp=85027693458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027693458&partnerID=8YFLogxK

U2 - 10.2967/jnumed.117.192450

DO - 10.2967/jnumed.117.192450

M3 - Article

C2 - 28473600

AN - SCOPUS:85027693458

VL - 58

SP - 1793

EP - 1796

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 11

ER -